Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jasmin Khan-Boluki"'
Autor:
Mieczysław Szalecki, Hans-Peter Schwarz, Dorota Birkholz-Walerzak, Corina Galesanu, Mieczysław Walczak, David Metreveli, Ellen Schuck, Jasmin Khan-Boluki
Publikováno v:
Biologics in Therapy
Background This prospective, open-label, non-comparative, multicentre, long-term phase IV study is examining the efficacy and safety of somatropin [recombinant human growth hormone (rhGH)] in short children born small for gestational age (SGA) and it
Autor:
Jochem König, Heinz Redl, Andreas Seekamp, Jasmin Khan-Boluki, Christian Rusu, Martijn van Griensven
Publikováno v:
European Journal of Trauma. 31:557-567
This prospective phase II parallel-group, double- blind, randomized, placebo-controlled clinical trial was meant to evaluate the effect of a humanized monoclonal anti-L-selectin antibody (aselizumab) on the posttraumatic inflammatory response in seve
Autor:
Jasmin, Khan-Boluki, Ferdinand, Hundt
Publikováno v:
GMS German Medical Science
Many prescribed treatments for children have not been adequately tested in children, sometimes resulting in harmful treatments being given and beneficial treatments being withheld. In the absence of specific trial-based data in children, results of s
Autor:
M. Diefenbeck, Erwin Dhondt, Heinz Redl, Michael Beckert, Martijn van Griensven, Piotr Dziurdzik, Ulrich Schaechinger, Ansgar M. Brambrink, Jan Stroobants, Andreas Seekamp, Laura Wolowicka, Ingo Marzi, Jasmin Khan-Boluki, Jacek Gasiorowski, Stefan Rammelt, Norbert P. Haas, Ignace Demeyer, Guy Vundelinckx
Publikováno v:
Critical care medicine. 32(10)
The objectives of this study were to evaluate safety (primary) and clinical efficacy (secondary) of the humanized monoclonal anti-L-selectin antibody aselizumab in severely injured patients.Prospective phase II, parallel group, double-blind, randomiz
Publikováno v:
Shock. 21:130